Prevail therapeutics inc. (PRVL)
CashFlow / Yearly
Dec'19Dec'18
Cash flows from operating activities
Net loss

-63,188

-19,087

Adjustments to reconcile net loss to net cash used in operating activities
Depreciation

265

55

Stock-based compensation

4,311

1,610

Amortization of convertible note discount, issuance costs and other non-cash interest

-

471

Change in fair value of derivative liabilities

-

781

Other

-

-12

Changes in operating assets and liabilities
Prepaid expenses and other current assets

5,847

459

Operating lease right-of-use asset

1,637

485

Accounts payable

3,921

976

Accrued expenses and other current liabilities

3,853

1,328

Operating lease liabilities

-706

-183

Net cash used in operating activities

-55,754

-14,011

Cash flows from investing activities
Purchases of property and equipment

2,136

627

Net cash used in investing activities

-2,136

-627

Cash flows from financing activities
Proceeds from issuance of common stock

116,251

-

Payment of issuance costs for preferred stock

166

93

Payment of issuance costs for common stock

3,210

-

Proceeds from exercise of stock options

52

-

Net cash provided by financing activities

162,927

64,907

Net increase (decrease) in cash, cash equivalents and restricted cash

105,037

50,269

Supplemental disclosure of non-cash investing and financing activities
Conversion of convertible note plus accrued interest into 1,330,369 shares of Series A Preferred Stock

-

11,279

Right-of-use asset obtained in exchange for operating lease obligation

3,104

7,740

Conversion of preferred stock to common stock upon the initial public offering

129,543

-

Series A Preferred Stock
Proceeds from issuance of Preferred Stock

-

65,000

Series B Preferred Stock
Proceeds from issuance of Series B Preferred Stock

50,000

-